Welcome to our dedicated page for Scinai Immunotherapeutics news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics stock.
Scinai Immunotherapeutics Ltd. reports developments as a Nasdaq-listed biopharmaceutical issuer with American Depositary Shares and a dual model spanning inflammation and immunology R&D and contract development and manufacturing services. Its updates cover the PC111 monoclonal antibody program targeting soluble Fas Ligand for severe dermatological and autoimmune conditions, next-generation NanoAb-based programs, and development rights or research funding tied to its immunology pipeline.
Company news also covers the CDMO platform operated through Scinai Biopharma Services Ltd., including the completed acquisition of Recipharm Israel, manufacturing capabilities across biologics and small-molecule programs, customer service expansion, operating results, material agreements, shareholder matters, capital-structure disclosures, and Nasdaq listing compliance for its ADSs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.